Abixa Adverse Reactions

In clinical trials in mild to severe dementia, involving 1,784 patients treated with Abixa and 1,595 patients treated with placebo, the overall incidence rate of adverse reactions with Abixa did not differ from those with placebo; the adverse events were usually mild to moderate in severity. The most frequently occurring adverse reactions with a higher incidence in the Abixa group than in the placebo group were dizziness (6.3% vs 5.6%, respectively), headache (5.2% vs 3.9%), constipation (4.6% vs 2.6%), somnolence (3.4% vs 2.2%) and hypertension (4.1% vs 2.8%).
The following Adverse Reactions listed in the Table as follows have been accumulated in clinical studies with Abixa and since its introduction in the market. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Adverse reactions are ranked according to system organ class, using the following convention: very common (≥1/10), common (≥1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data). (See table.)


Click on icon to see table/diagram/image


Alzheimer's disease has been associated with depression, suicidal ideation and suicide. In post-marketing experience these events have been reported in patients treated with Abixa.